AMGEN Reports Positive Topline Phase 3 Results For Subcutaneous Tepezza In Thyroid Eye Disease

Amgen announced positive Phase 3 topline results for TEPEZZA (teprotumumab-trbw) administered subcutaneously via an on-body injector in participants with moderate-to-severe disease. The result supports a potentially new, more convenient administration route for an existing commercial-stage therapy, which could broaden patient access and boost commercial uptake if full data and regulatory pathways are favorable. Expect the news to be materially positive for Amgen shares (single-digit percent move potential) pending full data release and regulatory clarity.

Analysis

Amgen announced positive Phase 3 topline results for TEPEZZA (teprotumumab-trbw) administered subcutaneously via an on-body injector in participants with moderate-to-severe disease. The result supports a potentially new, more convenient administration route for an existing commercial-stage therapy, which could broaden patient access and boost commercial uptake if full data and regulatory pathways are favorable. Expect the news to be materially positive for Amgen shares (single-digit percent move potential) pending full data release and regulatory clarity.